Meghmani Finechem Ltd

Epigral Limited has announced the closure of its trading window for all insiders, directors, promoters, designated persons, and their immediate relatives. This closure will be effective from Wednesday, July 1, 2026, and will remain in effect for 48 hours after the declaration of the Un-Audited Financial Results for the First Quarter ended June 30, 2026. The company is utilizing Central Depository Service Limited to restrict trading by freezing PAN at the security level for its ISIN, in compliance with SEBI regulations. The date for the Board Meeting to approve these financial results will be announced later.

Epigral Ltd has announced that its 19th Annual General Meeting (AGM) will be held on June 8, 2026, via video conferencing. The company has fixed June 1, 2026, as the cut-off date for e-voting eligibility and also as the record date to determine shareholders' entitlement for dividend for FY 2025-26, if approved. Remote e-voting will be available from June 4 to June 7, 2026. The Annual Report for FY 2025-26 and the AGM notice are available on the company's website.

Epigral Ltd has announced its 19th Annual General Meeting (AGM) scheduled for June 8, 2026, to be held via video conferencing. The company has fixed June 1, 2026, as the record date for dividend entitlement for FY 2025-26, subject to shareholder approval. Remote e-voting will be available from June 4 to June 7, 2026, with June 1, 2026, as the cut-off date to determine e-voting eligibility. The annual report for FY 2025-26, including the AGM notice, is available on the company's website.

Epigral Ltd has released its Business Responsibility and Sustainability Report (BRSR) for the financial year 2025-26, as per SEBI regulations. The report, available on the company's website, details the company's ESG performance, covering environmental impact, social responsibility, and governance practices. Key details include the company's CIN (L24100GJ2007PLC051717), registered office address, and financial figures such as paid-up capital of ₹43,14,13,380. The company's primary business activity is the manufacturing and selling of chemicals, contributing 100% to its turnover.

Epigral Ltd has announced the record date for the purpose of the 19th Annual General Meeting (AGM) and payment of dividend, if declared, for the financial year ended March 31, 2026. The record date is set for Monday, June 01, 2026. The AGM is scheduled for Monday, June 8, 2026, and will be held through Video Conferencing / Other Audio Visual Means.

The Board of Directors of Epigral Ltd recommended a final dividend of ₹5.00 (50.00%) per equity share with a face value of ₹10 each for the financial year 2025-26. This decision was made during the board meeting held on May 2, 2026, where the audited financial results for the fourth quarter and year ended March 31, 2026, were also approved.

Epigral Ltd's Board of Directors approved the audited standalone and consolidated financial results for the fourth quarter and year ended March 31, 2026, in a meeting held on May 2, 2026. The board also approved the audit report issued by M/s. S R B C & CO LLP with an unmodified opinion. A final dividend of ₹5.00 (50%) per equity share of face value ₹10 each was recommended for the financial year 2025-26.

Epigral Ltd reported a record Q4FY26 revenue of ₹736 crore, a 17% increase from ₹631 crore in Q4FY25. Profit After Tax (PAT) stood at ₹82 crore. The Board proposed a final dividend of ₹5 per equity share. Revenue grew by 22% sequentially, driven by improved volumes and realizations. EBITDA margin improved to 23% from 17% in Q3FY26. The company's capex projects for Epichlorohydrin and CPVC expansion are progressing as planned.

Epigral Ltd's Board of Directors approved the audited standalone and consolidated financial results for the fourth quarter and year ended March 31, 2026. The board also recommended a final dividend of ₹5.00 (50%) per equity share of face value ₹10 each for the financial year 2025-26. The audit report, issued by M/s. S R B C & CO LLP, had an unmodified opinion on the financial statements. The board meeting was held on May 2, 2026.

Epigral Ltd has scheduled a Board of Directors meeting on May 2, 2026, to consider and approve the audited financial results for the fourth quarter and year ended March 31, 2026. The board will also consider the recommendation of a final dividend, if any, on the equity shares.